Jeffrey Letzer, DO
Hematology & Oncology · Fort Wayne, INNPI 1760481766
Payments from drug & device makers
Across 184 payments — averaging $4147.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$221K
- Novartis$196K
- Astrazeneca UK Limited$186K
- Incyte Corporation$95K
- Amgen$40K
- Rigel Pharmaceuticals, Inc.$9K
- plus $17K from 29 others
Across 5 payments — averaging $104.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$523
What the payments were for
- Consulting fees$8,15744%
- Speaking & faculty fees$5,60030%
- Travel & lodging$1,0956%
- Food & beverage$3,59919%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $220,579 |
| Novartis | 14 | $196,002 |
| Astrazeneca UK Limited | 8 | $185,977 |
| Incyte Corporation | 25 | $94,778 |
| Amgen | 7 | $39,698 |
| Rigel Pharmaceuticals, Inc. | 6 | $8,620 |
| Syndax Pharmaceuticals, Inc. | 9 | $4,078 |
| Ipsen Biopharmaceuticals, Inc | 2 | $3,450 |
| Sanofi | 3 | $2,207 |
| ADC Therapeutics America, Inc. | 3 | $2,197 |
| Merck | 6 | $1,783 |
| Morphosys, US Inc. | 1 | $1,455 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $388 |
| Tempus AI, Inc | 6 | $381 |
| Johnson & Johnson(2 entities) | 14 | $259 |
| AstraZeneca(2 entities) | 5 | $220 |
| Sobi, Inc | 1 | $200 |
| Bristol Myers Squibb | 7 | $174 |
| Gilead | 2 | $138 |
| Secura Bio, Inc. | 1 | $99 |
| Jazz Pharmaceuticals Inc. | 1 | $88 |
| Coherus Oncology, Inc. | 1 | $75 |
| Genentech USA, Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Pfizer | 2 | $24 |
| AMAG Pharmaceuticals, Inc. | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $16 |
| GSK | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Servier Pharmaceuticals LLC | 1 | $14 |
| Dova Pharmaceuticals | 1 | $12 |
| Aurobindo Pharma USA, Inc. | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $7 |
| Fortovia Therapeutics, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$763,089 in reported general payments places this provider in the 90th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 51 | $828,756 |
| RevlimidLenalidomide | 33 | $634,286 |
| CalquenceAcalabrutinib Maleate | 38 | $567,017 |
| PomalystPomalidomide | 23 | $516,927 |
| BosulifBosutinib | 11 | $207,494 |
| TavalisseFostamatinib Disodium | 12 | $168,790 |
| EliquisApixaban | 148 | $163,352 |
| BrukinsaZanubrutinib | 12 | $116,209 |
| XareltoRivaroxaban | 98 | $99,488 |
| ImbruvicaIbrutinib | 11 | $64,350 |
| VenclextaVenetoclax | 17 | $60,441 |
| Posaconazole | 12 | $30,876 |
| Acyclovir | 119 | $3,282 |
| Enoxaparin Sodium | 14 | $3,043 |
| Imatinib Mesylate | 26 | $1,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $174 | $634,28633 claims |
| AstraZenecaCalquence | $220 | $567,01738 claims |
| PfizerBosulif, Eliquis | $24 | $370,846159 claims |
| Rigel Pharmaceuticals, Inc.Tavalisse | $8,620 | $168,79012 claims |
| Johnson & JohnsonXarelto | $259 | $99,48898 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $388 | $64,35011 claims |
| AbbVieVenclexta | $220,579 | $60,44117 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $26 | $3,282119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Fort Wayne
- Zhentao ZhangFort Wayne$6.4M
- Ahad SadiqFort Wayne$4M
- Naga Malleswari VutukuriFort Wayne$340K
- Melanie ClarkFort Wayne$281K
- Robert MangesFort Wayne$270K
- Sreenivasa NattamFort Wayne$122K
- Praveen KolliparaFort Wayne$88K
- Dolly Quispe LeveauFort Wayne$74K
- Gregory DurmIndianapolis$22.7M
- Nabil AdraIndianapolis$13.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.